
BCRX Valuation
BioCryst Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings
BCRX Relative Valuation
BCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCRX is overvalued; if below, it's undervalued.
Historical Valuation
BioCryst Pharmaceuticals Inc (BCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.92 is considered Undervalued compared with the five-year average of -34.44. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 15.26 to 45.62 according to relative valuation methord. Compared to the current price of 8.54 USD , BioCryst Pharmaceuticals Inc is Undervalued By 44.01%.
Relative Value
Fair Zone
15.26-45.62
Current Price:8.54
44.01%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
-3.98
P/B
Median3y
-4.65
Median5y
-11.58
-1.49
FCF Yield
Median3y
-6.89
Median5y
-7.43
Competitors Valuation Multiple
The average P/S ratio for BCRX's competitors is 17.15, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX) exhibits a P/S ratio of 2.92, which is -82.96% above the industry average. Given its robust revenue growth of 56.89%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch

CSGS
Csg Systems International Inc
62.610
USD
-1.12%

ZUO
Zuora Inc
10.080
USD
+0.30%

UA
Under Armour Inc
6.865
USD
+1.25%

PLYA
Playa Hotels & Resorts NV
13.480
USD
-0.07%

SSRM
SSR Mining Inc
12.450
USD
-0.88%

BV
Brightview Holdings Inc
16.470
USD
+1.54%

WS
Worthington Steel Inc
31.935
USD
+1.00%

NHC
National Healthcare Corp
96.800
USD
+2.46%

SASR
Sandy Spring Bancorp Inc
27.980
USD
+1.25%

VRNT
Verint Systems Inc
22.190
USD
+0.29%
FAQ

Is BioCryst Pharmaceuticals Inc (BCRX) currently overvalued or undervalued?
BioCryst Pharmaceuticals Inc (BCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.92 is considered Undervalued compared with the five-year average of -34.44. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 15.26 to 45.62 according to relative valuation methord. Compared to the current price of 8.54 USD , BioCryst Pharmaceuticals Inc is Undervalued By 44.01% .

What is BioCryst Pharmaceuticals Inc (BCRX) fair value?

How does BCRX's valuation metrics compare to the industry average?

What is the current P/B ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jul 25 2025?

What is the current FCF Yield for BioCryst Pharmaceuticals Inc (BCRX) as of Jul 25 2025?

What is the current Forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jul 25 2025?
